ସାକିଟୁଜୁମାବ ଗୋଭିଟେକାନ

ସାକିଟୁଜୁମାବ ଗୋଭିଟେକାନ
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Trop-2
Clinical data
Trade names	Trodelvy
Synonyms	IMMU-132, hRS7-SN-38, sacituzumab govitecan-hziy
AHFS/Drugs.com	monograph
MedlinePlus	a620034
data	US DailyMed: Sacituzumab_govitecan;
Pregnancy; category	Contraindicated;
Routes of; administration	Intravenous
Legal status
Legal status	US: ℞-only ;
Chemical and physical data
Formula	C76H104N12O24S
Molar mass	୧,୬୦୧.୭୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)OC(=O)OCC5=CC=C(C=C5)NC(=O)C(CCCCN)NC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN6C=C(N=N6)CNC(=O)C7CCC(CC7)CN8C(=O)CC(C8=O)SCC(C(=O)O)N)C2=NC9=C1C=C(C=C9)O;
	InChI InChI=1S/C76H104N12O24S/c1-3-55-56-37-54(89)16-17-61(56)83-68-57(55)43-87-63(68)38-59-58(71(87)95)45-110-74(99)76(59,4-2)112-75(100)111-44-50-10-14-52(15-11-50)81-70(94)62(7-5-6-18-77)82-66(91)47-109-46-65(90)79-19-21-101-23-25-103-27-29-105-31-33-107-35-36-108-34-32-106-30-28-104-26-24-102-22-20-86-42-53(84-85-86)40-80-69(93)51-12-8-49(9-13-51)41-88-67(92)39-64(72(88)96)113-48-60(78)73(97)98/h10-11,14-17,37-38,42,49,51,60,62,64,89H,3-9,12-13,18-36,39-41,43-48,77-78H2,1-2H3,(H,79,90)(H,80,93)(H,81,94)(H,82,91)(H,97,98)/t49?,51?,60-,62-,64?,76-/m0/s1; Key:ULRUOUDIQPERIJ-PQURJYPBSA-N;

ସାକିଟୁଜୁମାବ ଗୋଭିଟେକାନ, ଏକ ବିକ୍ରୟ ନାମ ଟ୍ରୋଡେଲଭି, ହେଉଛି ଏକ ଔଷଧ ଯାହା ତ୍ର-ବିଯୁକ୍ତାତ୍ମକ ସ୍ତନ କର୍କଟ (ଟ୍ରିପଲ୍-ନେଗେଟିଭ୍ ସ୍ତନ କର୍କଟ) ଏବଂ ୟୁରୋଥେଲିଆଲ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ^[୧] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ କର୍କଟ ବ୍ୟାପି ଯାଇଥାଏ ଏବଂ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହୋଇଥାଏ ।^[୩] ଏହା ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ନିମ୍ନ ନିଉଟ୍ରୋଫିଲ୍ ସ୍ତର, ତରଳ ଝାଡ଼ା, ଥକ୍କା, ସ୍ୱଳ୍ପ ଲୋହିତ ରକ୍ତ କଣିକା, ବାନ୍ତି, କେଶ ଝଡ଼ିବା, କୋଷ୍ଠକାଠିନ୍ୟ, ଅରୁଚି, ରାସ ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୩] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅନୁର୍ବରତା ଏବଂ ଆନାଫାଇଲାକ୍‌ସିସ ହୋଇପାରେ ।^[୩] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୫] ଏହା ଏକ ଟ୍ରୋପ-୨-ନିର୍ଦ୍ଦେଶିତ ( TROP-2-directed) ଆଣ୍ଟିବଡି ଯାହା ଟୋପୋଆଇସୋମରେଜ ଇନହିବିଟର ସହିତ ଯୋଡ଼ି ହୋଇ ରହିଛି ।^[୩] ^[୪]

୨୦୨୦ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ସାକିଟୁଜୁମାବ ଗୋଭିଟେକାନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୩] ୨୦୨୧ ସୁଦ୍ଧା ଯୋଗାଣ ଅଭାବ ହେତୁ ଏହା ୟୁରୋପରେ ଉପଲବ୍ଧ ନୁହେଁ ।^[୬] ଏହାର ଚିକିତ୍ସା ପାଇଁ ୭୦ କିଲୋଗ୍ରାମ ବ୍ୟକ୍ତିଙ୍କ ପାଇଁ ୨୦୨୧ ସୁଦ୍ଧା ବର୍ଷକୁ ପ୍ରାୟ ୩୧୦,୫୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20 March 2021. Retrieved 9 April 2021.
↑ "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments". U.S. Food and Drug Administration (FDA). 22 April 2020. Archived from the original on 23 April 2020. Retrieved 22 April 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Sacituzumab Govitecan-hziy Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 June 2021. Retrieved 9 October 2021.
↑ ^୪.୦ ^୪.୧ "Sacituzumab govitecan". SPS - Specialist Pharmacy Service. 10 February 2016. Archived from the original on 3 October 2021. Retrieved 9 October 2021.
↑ "Sacituzumab govitecan (Trodelvy) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 9 October 2021.
↑ "Availability of Trodelvy for European triple negative breast cancer patients". www.europarl.europa.eu (in ଇଂରାଜୀ). Archived from the original on 9 October 2021. Retrieved 9 October 2021.
↑ "Trodelvy Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 9 October 2021.

[Trodelvy_FDA_label-1] ୧.୦ ^୧.୧ "Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20 March 2021. Retrieved 9 April 2021.

[FDA_PR-2] "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments". U.S. Food and Drug Administration (FDA). 22 April 2020. Archived from the original on 23 April 2020. Retrieved 22 April 2020.

[AHFS2021-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Sacituzumab Govitecan-hziy Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 June 2021. Retrieved 9 October 2021.

[SP2021-4] ୪.୦ ^୪.୧ "Sacituzumab govitecan". SPS - Specialist Pharmacy Service. 10 February 2016. Archived from the original on 3 October 2021. Retrieved 9 October 2021.

[Preg2021-5] "Sacituzumab govitecan (Trodelvy) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 9 October 2021.

[6] "Availability of Trodelvy for European triple negative breast cancer patients". www.europarl.europa.eu (in ଇଂରାଜୀ). Archived from the original on 9 October 2021. Retrieved 9 October 2021.

[7] "Trodelvy Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Retrieved 9 October 2021.

[୨]

[୧]

[୩]

[୪]

[୫]

[୬]

[୭]